Giant retroperitoneal liposarcoma
- PDF / 4,200,436 Bytes
- 6 Pages / 610 x 792 pts Page_size
- 107 Downloads / 189 Views
Open Access
Case report
Giant retroperitoneal liposarcoma Ángel Herrera-Gómez1, César Ortega-Gutiérrez*1, Alejandro Mohar Betancourt2 and Kuauhyama Luna-Ortiz1 Address: 1Department of Surgical Oncology, Instituto Nacional de Cancerología, México, D.F., Mexico and 2Department of Pathology, Instituto Nacional de Cancerología, México, D.F., Mexico Email: Ángel Herrera-Gómez - [email protected]; César Ortega-Gutiérrez* - [email protected]; Alejandro Mohar Betancourt - [email protected]; Kuauhyama Luna-Ortiz - [email protected] * Corresponding author
Published: 31 October 2008 World Journal of Surgical Oncology 2008, 6:115
doi:10.1186/1477-7819-6-115
Received: 6 June 2008 Accepted: 31 October 2008
This article is available from: http://www.wjso.com/content/6/1/115 © 2008 Herrera-Gómez et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: Liposarcoma is the most frequent histopathological variety of the retroperitoneum, surgery is the gold standard for treatment. Case presentation: We present the case of a 24-year-old male who was diagnosed with a giant retroperitoneal liposarcoma. The patient received palliative treatment due to non-resectability on the basis of chemotherapy. We decided to perform surgery after no benefit was received with systemic treatment. Complete macroscopic resection of the tumor was performed, without multiorgan resection. The patient is currently alive and disease free at 14 months of evolution. Conclusion: Retroperitoneal liposarcomas represent a unique situation and require a more aggressive surgical approach including multiple resections for recurrences. Based on the ability of the patient to tolerate the procedure, surgery is suggested to evaluate resectability of the tumor. We must take into consideration whether prolonged survival will be attained and tumor removal will result in palliation of symptoms.
Background Liposarcomas are neoplasms of mesodermic origin derived from adipose tissue and correspond to 10–14% of all soft tissue sarcomas. They represent < 1% of all malignant tumors [1,2]. The most frequent subtypes are liposarcoma (41%), leiomyosarcoma (28%), malignant fibrous histiocytoma (7%), fibrosarcoma (6%) and tumors of the peripheral nerve sheath (3%) [3]. Retroperitoneal liposarcomas alone comprise 0.07–0.2% of all neoplasias4. Approximately 85% of these are malignant, with soft-tissue sarcomas representing 35% of this group. Liposarcoma is the most frequent histopathological variety of the retroperito-
neum [2]. It presents with inherent characteristics in relation to its deep localization and slow expansive growth. Average diameter of the tumor is 20–25 cm with a weight of 15–20 kg [4]. There is compromise of the adjacent organs in up to 80% of the cases [4,5]. Surgery is the
Data Loading...
